Improving detection of lung nodules using advanced imaging technology
Ultra-long Field-Of-View Positron Emission Tomography for Characterization of Indeterminate Lung Nodules: a Pilot Study Exploring Opportunities for Clinical Research
PHASE4 · University Medical Center Groningen · NCT05463913
This study is testing a new type of imaging technology to see if it can better detect small lung nodules in patients and help doctors figure out if they are cancerous or not.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University Medical Center Groningen (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Groningen) |
| Trial ID | NCT05463913 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of ultra-long Field-Of-View PET/CT scanners in detecting indeterminate lung nodules sized 6-15 mm, which are commonly found in patients undergoing chest CT scans. The research aims to enhance early detection and diagnosis of lung cancer by assessing the sensitivity and image quality of this new imaging technology compared to traditional methods. Participants will undergo routine 18F-FDG PET/CT imaging as part of their clinical care, and the study will evaluate the technical performance of this approach in differentiating malignant from benign nodules. The goal is to improve follow-up procedures and reduce the need for repeated CT scans, thereby minimizing radiation exposure and patient anxiety.
Who should consider this trial
Good fit: Ideal candidates are patients with confirmed indeterminate lung nodules of 6-15 mm who are scheduled for biopsy or resection.
Not a fit: Patients with claustrophobia, those who are pregnant or breastfeeding, or individuals with uncontrolled diabetes may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate detection of lung cancer, improving patient outcomes.
How similar studies have performed: While there have been advancements in imaging technologies, this specific approach using ultra-long FOV PET/CT is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * able to give informed consent * signed informed consent * confirmed indeterminate lung nodule(s) of 6-15 mm in size on CT chest imaging * routine 18F-FDG PET/CT performed * scheduled for biopsy or resection of the lung nodules Exclusion Criteria: * claustrophobia * pregnant or breastfeeding * interval of at least 2 weeks between PET scan and last date of systemic anti-cancer therapy to reduce false-negative uptake in lesions * radiation therapy of the target lung nodule(s) * uncontrolled diabetes mellitus * any medical condition potentially hampering conduction of the trial
Where this trial is running
Groningen
- University Medical Center Groningen — Groningen, Netherlands (RECRUITING)
Study contacts
- Principal investigator: Adrienne H Brouwers, MD PhD — Nuclear Medicine physician
- Study coordinator: Adrienne H Brouwers, MD PhD
- Email: a.h.brouwers@umcg.nl
- Phone: +31503613093
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer